Compare ABRDN Physical Gold Shares ETF (SGOL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.5 (market cap $7.18B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: ABRDN Physical Gold Shares ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SGOL | TVTX | |
|---|---|---|
Market Cap | $7.18B | $4.88B |
Volume | 2,482,796 | 1,668,577 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $67.52 |
52-Week Low | $37.54 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.63, down 0.13% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX showing sell signals. Support levels cluster around $39-40, while resistance is firm at $40. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices pressured by rising rates but supported by geopolitical tensions and strong Chinese imports.
The outlook remains cautious amid interest rate uncertainty, with potential for rebound if yields stabilize or conflict escalates. Risks include persistent inflation driving higher rates, while institutional analysts see mixed paths—some targeting $4,100 by year-end but others $5,000 by mid-2027. Investor sentiment is neutral to bearish short-term.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
